Medpace Q3 revenue rises 8.5%, slightly beats analyst estimates
MEDP•Medpace reported Q3 revenue of $716 million, up 8.5% and slightly above estimates, and net income of $137.46 million. It authorized a new $1 billion share repurchase program and forecast 2026 revenue of $2.835 billion to $2.855 billion.
1. Quarterly results
Medpace’s Q3 revenue rose 8.5% year on year to $716 million, slightly above the $715.98 million analyst consensus. Net income was $137.46 million, and net income margin rose to 19.2%. Net new business awards increased 10.6% to $873.4 million.
2. 2026 outlook and buyback
The company forecast 2026 revenue of $2.835 billion to $2.855 billion, GAAP net income of $514 million to $524 million, and diluted EPS of $17.97 to $18.32. It approved a new $1 billion share repurchase authorization, replacing its prior program.
